摘要:

Hematopoietic growth factors, including granulocyte colony-stimulating factor (G-CSF), are being increasingly used to prevent chemotherapy-induced neutropenia. We report a patient with aggressive non-Hodgkin's lymphoma who was successfully supported with G-CSF through a weekly VACOP-B chemotherapy regimen. The patient had become severely neutropenic at week 3, requiring a one-week delay. For the remainder of the treatment, G-CSF at a dose of 4μg/kg/day was administered daily over 4 days after week 4, then over 3 days thereafter, beginning the day after the non-myelosuppressive weeks (vincristine/bleomycin). A total of 5 such G-CSF courses were given, with no further neutropenia despite administration of full chemotherapy doses on schedule. This case suggests that, at least with the VACOP-B regimen, chemotherapy-induced neutropenia can be prevented using much lower quantities of G-CSF than has been reported using other regimens.

ISSN:1042-8194    

DOI:10.3109/10428199309067942

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

摘要:

Specific morphological and histochemical changes serve to define stages of differentiation during terminal myeloid maturation. The development of the hybridoma technology has allowed generation of monoclonal antibodies selectively reactive with antigenic determinants expressed in the hematopoietic system by myeloid cells at specific stages of differentiation. Here, the characterization by one of these antibodies i.e. GO35 (CD17) which shows myeloid specificity, was reported on blastic cells from 30% of acute lymphoid leukemia cases investigated (8/25). This monoclonal antibody may prove useful in the subclassification of atypical lymphoproliferative disorders including“hybrid leukemias”and serve as a possible prognostic factor for a therapy.

ISSN:1042-8194    

DOI:10.3109/10428199309067943

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor

ISSN:1042-8194    

DOI:10.3109/10428199309067944

出版商:Taylor&Francis    

年代:1993

数据来源: Taylor